202 related articles for article (PubMed ID: 1325351)
1. Effects of diltiazem and verapamil on (+)-PN 200-110 binding kinetics in dog cardiac membranes.
Miwa K; Miyagi Y; Araie E; Sasayama S
Eur J Pharmacol; 1992 Apr; 214(2-3):127-32. PubMed ID: 1325351
[TBL] [Abstract][Full Text] [Related]
2. Calcium ions inhibit the allosteric interaction between the dihydropyridine and phenylalkylamine binding site on the voltage-gated calcium channel in heart sarcolemma but not in skeletal muscle transverse tubules.
Murphy BJ; Tuana BS
Can J Physiol Pharmacol; 1990 Nov; 68(11):1389-95. PubMed ID: 1962734
[TBL] [Abstract][Full Text] [Related]
3. Molecular approach to the calcium channel.
Glossmann H; Ferry DR; Goll A; Linn T
Adv Myocardiol; 1985; 5():41-76. PubMed ID: 2578683
[TBL] [Abstract][Full Text] [Related]
4. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
[TBL] [Abstract][Full Text] [Related]
5. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
Hagiwara M; Adachi-Akahane S; Nagao T
J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
[TBL] [Abstract][Full Text] [Related]
6. Interaction of pinaverium (a quaternary ammonium compound) with 1,4-dihydropyridine binding sites in rat ileum smooth muscle.
Feron O; Wibo M; Christen MO; Godfraind T
Br J Pharmacol; 1992 Feb; 105(2):480-4. PubMed ID: 1313732
[TBL] [Abstract][Full Text] [Related]
7. Effects of four diltiazem stereoisomers on binding of d-cis-[3H]diltiazem and (+)-[3H]PN200-110 to rabbit T-tubule calcium channels.
Ikeda S; Oka J; Nagao T
Eur J Pharmacol; 1991 Nov; 208(3):199-205. PubMed ID: 1663043
[TBL] [Abstract][Full Text] [Related]
8. Allosteric interaction of semotiadil fumarate, a novel benzothiazine, with 1,4-dihydropyridines, phenylalkylamines, and 1,5-benzothiazepines at the Ca(2+)-channel antagonist binding sites in canine skeletal muscle membranes.
Nakayama K; Nozawa Y; Fukuta Y
J Cardiovasc Pharmacol; 1994 May; 23(5):731-40. PubMed ID: 7521455
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the binding site of [3H]-d-cis-diltiazem and that of other non-dihydropyridine calcium entry blockers in cardiac sarcolemma.
Balwierczak JL; Johnson CL; Schwartz A
Mol Pharmacol; 1987 Feb; 31(2):175-9. PubMed ID: 2433570
[TBL] [Abstract][Full Text] [Related]
10. Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors.
Garcia ML; King VF; Siegl PK; Reuben JP; Kaczorowski GJ
J Biol Chem; 1986 Jun; 261(18):8146-57. PubMed ID: 2424894
[TBL] [Abstract][Full Text] [Related]
11. Potential-dependent allosteric modulation of 1,4-dihydropyridine binding by d-(cis)-diltiazem and (+/-)-verapamil in living cardiac cells.
Porzig H; Becker C
Mol Pharmacol; 1988 Aug; 34(2):172-9. PubMed ID: 2457793
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the binding sites for nimodipine and (-)-desmethoxyverapamil in bovine cardiac sarcolemma.
Ruth P; Flockerzi V; von Nettelbladt E; Oeken J; Hofmann F
Eur J Biochem; 1985 Jul; 150(2):313-22. PubMed ID: 2990931
[TBL] [Abstract][Full Text] [Related]
13. Binding of the dihydropyridine calcium channel blocker (+)-[3H] isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2, 6-dimethyl-3-pyridinecarboxylate (PN200-110) to RINm5F membranes and cells: characterization and functional significance.
Yaney GC; Stafford GA; Henstenberg JD; Sharp GW; Weiland GA
J Pharmacol Exp Ther; 1991 Aug; 258(2):652-62. PubMed ID: 1713965
[TBL] [Abstract][Full Text] [Related]
14. Identification, characterization, and photoaffinity labeling of the dihydropyridine receptor associated with the L-type calcium channel from bovine adrenal medulla.
Murphy BJ; Rogers CA; Sunahara RK; Lemaire S; Tuana BS
Mol Pharmacol; 1990 Feb; 37(2):173-81. PubMed ID: 2154669
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of binding of dihydropyridine calcium channel ligands to skeletal muscle membranes: evidence for low-affinity sites and for the involvement of G proteins.
Dunn SM; Bladen C
Biochemistry; 1991 Jun; 30(23):5716-21. PubMed ID: 1645998
[TBL] [Abstract][Full Text] [Related]
16. Characterization and photoaffinity labeling of receptor sites for the Ca2+ channel inhibitors d-cis-diltiazem, (+/-)-bepridil, desmethoxyverapamil, and (+)-PN 200-110 in skeletal muscle transverse tubule membranes.
Galizzi JP; Borsotto M; Barhanin J; Fosset M; Lazdunski M
J Biol Chem; 1986 Jan; 261(3):1393-7. PubMed ID: 3003067
[TBL] [Abstract][Full Text] [Related]
17. Separate [3H]-nitrendipine binding sites in mitochondria and plasma membranes of bovine adrenal medulla.
Ballesta JJ; Garcia AG; Gutierrez LM; Hidalgo MJ; Palmero M; Reig JA; Viniegra S
Br J Pharmacol; 1990 Sep; 101(1):21-6. PubMed ID: 1704272
[TBL] [Abstract][Full Text] [Related]
18. (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines.
Reynolds IJ; Snowman AM; Snyder SH
J Pharmacol Exp Ther; 1986 Jun; 237(3):731-8. PubMed ID: 3012067
[TBL] [Abstract][Full Text] [Related]
19. Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140.
Staudinger R; Knaus HG; Glossmann H
J Biol Chem; 1991 Jun; 266(17):10787-95. PubMed ID: 1645709
[TBL] [Abstract][Full Text] [Related]
20. The failure of endothelin to displace bound, radioactively-labelled, calcium antagonists (PN 200/110, D888 and diltiazem).
Gu XH; Liu JJ; Dillon JS; Nayler WG
Br J Pharmacol; 1989 Feb; 96(2):262-4. PubMed ID: 2538185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
